FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Josep Llibre

Research Profile

Disorders

HIV Infections

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Geographic Areas

Spain

Co-author Network

Publications

TOP 3
Eva Zetterberg; Jason V Baker; Maria Chini; Josep M Llibre; Jens D Lundgren; Jacqueline Neuhaus; Adrian Palfreeman; Charurut Somboonwit
Platelet count kinetics following interruption of antiretroviral treatment.
Lourdes Anta; José L Blanco; Estrella Caballero; Carmen de Mendoza; Josep M Llibre; María J Pérez-Elías; Eva Poveda; Vicente Soriano; Antonio Aguilera; Marta Alvarez
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Esteban Martínez; Xabier Moreno; Ignacio Perez; Judit Pich; Daniel Podzamczer; Antonio Antela; Juan Berenguer; Polyana M D'Albuquerque; Pere Domingo; José M Gatell; Felix Gutierrez; Josep M Llibre
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Josep Llibre (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eva Zetterberg; Jason V Baker; Maria Chini; Josep M Llibre; Jens D Lundgren; Jacqueline Neuhaus; Adrian Palfreeman; Charurut Somboonwit
Platelet count kinetics following interruption of antiretroviral treatment.
AIDS (London, England) 2013;27(1):59-68.
2013: Lourdes Anta; José L Blanco; Estrella Caballero; Carmen de Mendoza; Josep M Llibre; María J Pérez-Elías; Eva Poveda; Vicente Soriano; Antonio Aguilera; Marta Alvarez
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
AIDS (London, England) 2013;27(1):81-5.
2012: Esteban Martínez; Xabier Moreno; Ignacio Perez; Judit Pich; Daniel Podzamczer; Antonio Antela; Juan Berenguer; Polyana M D'Albuquerque; Pere Domingo; José M Gatell; Felix Gutierrez; Josep M Llibre
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
AIDS (London, England) 2012;26(18):2315-26.
2012: Josep M Llibre; Daniel Podzamczer
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
AIDS (London, England) 2012;26(16):2117-8.
2012: Eva Poveda; Federico Pulido; José Alcamí; Juan Córdoba; Rafael Delgado; Miguel García Deltoro; Félix Gutiérrez; José Hernández Quero; José Antonio Iribarren; Josep M Llibre; Santiago Moreno; Roger Paredes; Federico García
Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.
AIDS reviews 2012;14(3):208-17.
2012: Josep M Llibre; Bonaventura Clotet
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
AIDS reviews 2012;14(3):168-78.
2012: Gabriel V Sánchez; Jose R Santos; Arantza Sanvisens; Marta Torrens; Hernando Knobel; Klaus Langohr; Josep M Llibre; Gerard Mateu; Roberto Muga
Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy.
Current HIV research 2012;10(4):356-63.
2012: Antonio Javier Blasco; Vicente Boix; Bonaventura Clotet; Pere Domingo; Josep M Gatell; Juan González-García; Hernando Knobel; Pablo Lázaro; Josep M Llibre; Juan Carlos López; Fernando Lozano; José M Miró; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; José Ramón Arribas
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Enfermedades infecciosas y microbiología clínica 2012;30(6):283-93.
2012: José R Santos; Jonathan M Schapiro; Bonaventura Clotet; Pere Domingo; María José Galindo; Arkaitz Imaz; José A Iribarren; Josep M Llibre; Ana Mariño; Celia Miralles; Santiago Moreno; Arelly Ornelas
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
The Journal of antimicrobial chemotherapy 2012;67(6):1462-9.
2012: Gabriel Vallecillo; Josep Mallolas; Enric Pedrol; Jesús Blanch; Manuel Cervantes; Pere Domingo; Elena Ferrer; Hernando Knobel; Josep M Llibre
Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.
AIDS research and human retroviruses 2012;28(2):165-70.
2012: José R Santos; Isabel Bravo; Bonaventura Clotet; Josep M Llibre; José Moltó; Eugenia Negredo; Arelly Ornelas; Roger Paredes
Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
PloS one 2012;7(5):e37442.
2012: Josep M Llibre; Javier Martinez-Picado; Marta Massanella; Sarah Palmer; Maria C Puertas; Mario Stevenson; Viktor Dahl; Pere Domingo; Anna Esteve; Josep M Gatell; Mar Gutierrez; Maria Larrouse; Julià Blanco; Maria J Buzón; Bonaventura Clotet
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Antiviral therapy 2012;17(2):355-64.
2011: Antonio Javier Blasco; Bonaventura Clotet; Pere Domingo; José Ramón Arribas; Juan González-García; Pablo Lázaro; Josep M Llibre; Juan Carlos López-Bernaldo; Fernando Lozano; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; Josep M Gatell
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
Enfermedades infecciosas y microbiología clínica 2011;29(10):721-30.
2011: Maria J Buzón; Bonaventura Clotet; Francisco M Codoñer; Judith Dalmau; Simon D W Frost; Josep M Llibre; Marta Massanella; Roger Paredes; Christian Pou; Maria C Puertas; Mario Stevenson; Julià Blanco; Javier Martinez-Picado
Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
PLoS pathogens 2011;7(10):e1002314.
2011: Arkaitz Imaz; Josep M Llibre; Bonaventura Clotet; Esteban Ribera; Daniel Podzamczer
The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(2):e46-8.
2011: Josep M Llibre; Fernando Lozano; Santiago Moreno; Antonio Rivero; José R Santos; José R Arribas; Bonaventura Clotet; Pere Domingo; Josep M Gatell
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
AIDS (London, England) 2011;25(14):1683-90.
2011: José R Santos; Sebastián Videla; Isabel Bravo; Pere Domingo; Elena Ferrer; Arkaitz Imaz; Josep M Llibre; Daniel Podzamczer; Esteban Ribera; Bonaventura Clotet
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
AIDS research and human retroviruses 2011;27(7):713-7.
2011: MA Morera; Neus Sala; Sira Domènech; Josep M Llibre
[Encephalitis with multiple space occupying lesions in a patient with human immunodeficiency virus type 1 infection].
Enfermedades infecciosas y microbiología clínica 2011;29(3):227-9.
2011: Eva Heras; Josep M Llibre; Elisa Martró; Jordi Casabona; Raquel Martín; Raquel Martin-Iguacel; Guillem Sirera
[Lymphogranuloma venereum proctocolitis in men with HIV-1 infection].
Enfermedades infecciosas y microbiología clínica 2011;29(2):124-6.
2011: Arkaitz Imaz; Josep M Llibre; Marta Mora; Gracia Mateo; Angela Camacho; José R Blanco; Adria Curran; José R Santos; Estrella Caballero; Isabel Bravo; Francisco Gayá; Pere Domingo; Antonio Rivero; Vicenç Falcó; Bonaventura Clotet; Esteban Ribera
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
The Journal of antimicrobial chemotherapy 2011;66(2):358-62.
2011: Jonathan M Schapiro; Charles A B Boucher; Daniel R Kuritzkes; David A van de Vijver; Josep M Llibre; Marilyn Lewis; Paul Simpson; Christophe Delogne; Lynn McFadyen; Douglass Chapman; Manos Perros; Hernan Valdez; Elna van der Ryst; Mike Westby
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Antiviral therapy 2011;16(3):395-404.
2010: Josep M Llibre; Antonio Antela; José Ramón Arribas; Pere Domingo; Josep M Gatell; José López Aldeguer; Fernando Lozano; Celia Miralles; José Moltó; Santiago Moreno; Enrique Ortega; Melcior Riera; Antonio Rivero; Concepción Villalonga; Bonaventura Clotet
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].
Enfermedades infecciosas y microbiología clínica 2010;28(9):615-20.
2010: Esteban Martínez; María Larrousse; Josep M Llibre; Félix Gutiérrez; Maria Saumoy; Antonio Antela; Hernando Knobel; Javier Murillas; Juan Berenguer; Judit Pich; Ignacio Pérez; José M Gatell
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
AIDS (London, England) 2010;24(11):1697-707.
2010: Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark E Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nature medicine 2010;16(4):460-5.
2010: Josep M Llibre; Jonathan M Schapiro; Bonaventura Clotet
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(6):872-81.
2010: Josep M Llibre
Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.
Antiviral therapy 2010;15(7):959-61.
2009: Josep M Llibre; José Ramón Santos; Bonaventura Clotet
[Etravirine: genetic barrier and resistance development].
Enfermedades infecciosas y microbiología clínica 2009;27 Suppl 2():32-9.
2009: José R Santos; Josep M Llibre; Elena Ferrer; Pere Domingo; Arkaitz Imaz; José Moltó; Raquel Martin-Iguacel; Carme Caum; Daniel Podzamczer; Bonaventura Clotet
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
HIV clinical trials 2009;10(6):432-8.
2009: Josep M Llibre
First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better.
AIDS reviews 2009;11(4):215-22.
2009: Josep M Llibre; Vicenç Falco; Cristina Tural; Eugenia Negredo; Juan A Pineda; Jose Muñoz; Enrique Ortega; Sebastia Videla; Guillem Sirera; Esteban Martinez; Celia Miralles; Josean Iribarren; Maria J Galindo; Pere Domingo; Antonella d'Arminio Monforte; Jose M Miro; Bonaventura Clotet
The changing face of HIV/AIDS in treated patients.
Current HIV research 2009;7(4):365-77.
2009: Eva Heras; Josep M Llibre; Guillem Sirera; Jose L Mate; Vicente Boix; Celestino Rey-Joly; Bonaventura Clotet
Lymphogranuloma venerium proctitis in the setting of HIV: a case report and differential diagnosis.
AIDS patient care and STDs 2009;23(7):493-4.
2009: Esteban Martínez; José A Arranz; Daniel Podzamczer; Montserrat Loncá; José Sanz; Patricia Barragán; Esteban Ribera; Hernando Knobel; Victor Roca; Félix Gutiérrez; José L Blanco; Josep Mallolas; Josep M Llibre; Bonaventura Clotet; David Dalmau; Ferran Segura; José R Arribas; Jaime Cosín; Pilar Barrufet; Esperanza Casas; Elena Ferrer; Adrià Curran; Alicia González; Judit Pich; Ana Cruceta; Joan A Arnaiz; José M Miró; José M Gatell
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;51(3):290-7.
2009: Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda
How much fat loss is needed for lipoatrophy to become clinically evident?
AIDS research and human retroviruses 2009;25(6):563-7.
2009: José Ramón Santos; José Moltó; Josep M Llibre; Nuria Pérez; Cristina Miranda; Bonaventura Clotet
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
HIV clinical trials 2009;10(3):129-34.
2009: Josep Mallolas; Daniel Podzamczer; Ana Milinkovic; Pere Domingo; Bonaventura Clotet; Esteve Ribera; Félix Gutiérrez; Hernando Knobel; Jaime Cosin; Elena Ferrer; José Alberto Arranz; Victor Roca; Francesc Vidal; Javier Murillas; Judit Pich; Enric Pedrol; Josep M Llibre; David Dalmau; Isabel García; Miquel Aranda; Ana Cruceta; Esteban Martínez; José L Blanco; Elisa de Lazzari; José M Gatell
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):29-36.
2009: Daniel Podzamczer; Montserrat Olmo; Jose Sanz; Vicente Boix; Eugenia Negredo; Hernando Knobel; Pere Domingo; Juan A Pineda; Consuelo Vilades; Jose Hernandez Quero; Lluis Force; Juan Gonzalez Lahoz; Pepa Muñoz; Josep M Llibre; Ana Mariño; Enrique Ortega; David Dalmau; Josep M Gatell; Esperanza Antón; Julio Sola; María J Galindo; Enric Pedrol; Jesus Sanz; Javier Torre de Lima; Juan Flores
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Journal of acquired immune deficiency syndromes (1999) 2009;50(4):390-6.
2009: Carmen de Mendoza; Lourdes Anta; Federico García; M Jesús Pérez-Elías; Félix Gutiérrez; Josep M Llibre; Luis Menéndez-Arias; David Dalmau; Vincent Soriano
HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.
AIDS reviews 2009;11(1):39-51.
2008: Josep M Llibre; Javier Martínez-Picado
[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 12():17-22.
2008: Vicenç Falcó; Montserrat Olmo; Sara Villar del Saz; Ana Guelar; José R Santos; Mar Gutiérrez; Daniel Colomer; Elisabet Deig; Gracia Mateo; Milagro Montero; Enric Pedrol; Daniel Podzamczer; Pere Domingo; Josep M Llibre
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.
Journal of acquired immune deficiency syndromes (1999) 2008;49(1):26-31.
2008: Josep M Llibre; A Bonjoch; J Iribarren; María José Galindo; Eugenia Negredo; Pere Domingo; N Pérez-Alvarez; J Martinez-Picado; J Schapiro; Bonaventura Clotet
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
HIV medicine 2008;9(7):508-13.
2008: Josep M Llibre; Pere Domingo; Miguel A del Pozo; Celia Miralles; María José Galindo; Isabel Viciana; Santiago Moreno; Jonathan M Schapiro; Bonaventura Clotet
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
The Journal of antimicrobial chemotherapy 2008;61(1):206-9.
2007: Josep M Llibre; Núria Pérez-Alvarez
Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
HIV medicine 2007;8(8):568-70; author reply 571-2.
2007: Elena Ferrer; Jordi Niubo; Manel Crespo; José M Gatell; Jose Sanz; Sergio Veloso; Josep M Llibre; Pilar Barrufet; Pochita Sanchez; Daniel Podzamczer
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):253-5.
2007: Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montserrat Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-Lacasa; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; José Pedreira; Ana Lérida; Rafael Rubio; Luis del Río
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Journal of acquired immune deficiency syndromes (1999) 2007;44(2):139-47.
2007: Lidia Ruiz; Roger Paredes; Guadalupe Gómez; Joan Romeu; Pere Domingo; Núria Pérez-Alvarez; Giuseppe Tambussi; Josep M Llibre; Javier Martínez-Picado; Francesc Vidal; Carmina R Fumaz; Bonaventura Clotet
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
AIDS (London, England) 2007;21(2):169-78.
2006: José A Gómez-Puerta; Gerard Espinosa; José M Miró; Omar Sued; Josep M Llibre; Ricard Cervera; Josep Font
Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy.
The Israel Medical Association journal : IMAJ 2006;8(7):513-4.
2006: Josep M Llibre; Pere Domingo; Rosario Palacios; Jesús Santos; María Jesús Pérez-Elías; Rainel Sánchez-de la Rosa; Celia Miralles; Antonio Antela; Santiago Moreno
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
AIDS (London, England) 2006;20(10):1407-14.
2006: Anna Bonjoch; Roger Paredes; Pere Domingo; Manel Cervantes; Enric Pedrol; Esteban Ribera; Lluís Force; Josep M Llibre; Josep Vilaró; David Dalmau; Josep Cucurull; Jaume Mascaró; Angels Masabeu; Núria Pérez-Alvarez; Jordi Puig; Denise Cinquegrana; Bonaventura Clotet
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
AIDS research and human retroviruses 2006;22(4):321-9.
2005: Anna Ochoa de Echagüen; Mireia Arnedo; Mariona Xercavins; Esteban Martinez; Beatriz Rosón; Esteban Ribera; Pere Domingo; Alicia González; Melcior Riera; Josep M Llibre; José M Gatell; David Dalmau
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
AIDS (London, England) 2005;19(13):1385-91.
2004: Hernando Knobel; José M Miró; Beatriz Mahillo; Pere Domingo; Antonio Rivero; Esteban Ribera; Juan Gonzalez; José Sanz; Alicia González; José L Blanco; Vicente Boix; Lluís Force; Josep M Llibre; David Dalmau; Juan A Arroyo; Julián De la Torre; Dolors Rodriguez; María Luisa Montes; Alberto Arranz; María Sarasa
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Journal of acquired immune deficiency syndromes (1999) 2004;37(2):1276-81.
2004: Pere Domingo; Pablo Labarga; Rosario Palacios; Manuel Fernández Guerro; José Alberto Terrón; María J Elías; Jesús Santos; María I Ruiz; Josep M Llibre
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
AIDS (London, England) 2004;18(10):1475-8.
2004: Alfonso Casado; Xavier Badia; Ezequiel Consiglio; Elena Ferrer; Alicia González; Enric Pedrol; José M Gatell; C Azuaje; Josep M Llibre; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; Daniel Podzamczer
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
HIV clinical trials 2004;5(3):132-9.
2003: Esteban Martínez; Juan A Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; Melcior Riera; Enric Pedrol; Lluís Force; Josep M Llibre; Ferran Segura; Cristóbal Richart; Cristina Cortés; Manuel Javaloyas; Miquel Aranda; Anna Cruceta; Elisa De Lazzari; José M Gatell
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
The New England journal of medicine 2003;349(11):1036-46.
2003: Javier Martinez-Picado; Eugenia Negredo; Lidia Ruiz; Ayumi Shintani; Carmina R Fumaz; Carlos Zala; Pere Domingo; Josep Vilaró; Josep M Llibre; Pompeyo E. Viciana; Kurt Hertogs; Charles Boucher; Richard T D'Aquila; Bonaventura Clotet
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.
Annals of internal medicine 2003;139(2):81-9.
2002: Daniel Podzamczer; Elena Ferrer; Ezequiel Consiglio; José M Gatell; Pepa Perez; José Luis Perez; Elena Luna; Alicia González; Enric Pedrol; Luisa Lozano; Imma Ocaña; Josep M Llibre; Arnaldo Casiró; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; José M Miró; Xavier Badía; Alfonso Casado; Sergio Lupo; Pedro Cahn; Manel Maños; Jordi Estela
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Antiviral therapy 2002;7(2):81-90.
2002: Josep M Llibre; Joan Romeu; Estibaliz López; Guillem Sirera
Severe interaction between ritonavir and acenocoumarol.
The Annals of pharmacotherapy 2002;36(4):621-3.